Venkat Krishnamurthy
Chief Scientific Officer Flashpoint Therapeutics
Venkat Krishnamurthy, Ph.D., is serving as Chief Scientific Officer at Flashpoint Therapeutics, with more than 15 years of experience in RNA based therapeutics from discovery through clinical development. Prior to Joining Flashpoint, he served as Senior Vice President at Korro Bio, where he was responsible for building its RNA editing platform and advancing therapeutic programs from discovery into clinical development. Prior to Korro, he held leadership roles at Eli Lilly as Executive Director of Genetic Medicines and at AstraZeneca as a Team Lead for new modalities and non-viral delivery. Earlier in his career at Dicerna Pharmaceuticals, Dr. Krishnamurthy played an integral role in advancing the company’s siRNA platform, including the advancement of Nedosiran, an FDA approved product for the treatment of Primary Hyperoxaluria. He began his career as an Instructor at Harvard Medical School after a postdoctoral fellowship at Princeton University. He has authored more than 50 publications and patents and is widely recognized for his contributions to oligonucleotide chemistry, delivery systems, and RNA therapeutics.
Seminars
- Applying the discovery of spherical nucleic acids by Chad Mirkin’s laboratory at Northwestern University to multiple treatment modalities, including immuno-oncology, RNA therapeutics, non-viral gene therapy, gene editing, and in vivo CAR-T
- Improving stability and cellular uptake via precision-engineered architecture
- Avoiding hepatic accumulation and targeting disease-specific tissues
